1 October 2019 - There have been a host of changes at the UK’s Health Technology Assessment agency – NICE – over its 20 year history, and one of these relates to the option for companies to offer a deal that can then be taken into account by NICE.

The terminology isn’t strictly the offer of deals, instead there can be prices secured via the Commercial Medicines Unit (CMU) which is now part of NHS England, or a Commercial Arrangement (CA), Commercial Access Agreement (CAA), the Cancer Drugs Fund (CDF), the CDF along with a Managed Access Agreement (MAA), Discounted Price (DP), a MAA alone, a Patient Access Scheme (PAS) or Simple Discount Agreement (SDA).

Read Pharmaphorum article